The S&P/ASX 200 Index (ASX: XJO) has climbed higher again on Thursday morning, up around another 0.5%. The increase is great news after the index suffered consecutive declines over the past month. And now many investors are focused on ASX 200 shares that can continue climbing higher from here.

Here are three ASX 200 shares that broker forecasts suggest could jump up to 40% over the next 12 months.

Qantas Airways Ltd (ASX: QAN)

The ASX 200 airline shares were smashed lower earlier this year as conflict in the Middle East and rising fuel prices put airlines under pressure. There was a brief rebound around July, but recent renewal of geopolitical tensions has seen the share price tumble again over the past month.

Jet fuel (refined from crude oil) is the highest operating cost for airlines. That means that when oil prices increase amid tight supply and geopolitical tensions, jet fuel prices also jump. And this means that airlines, such as Qantas, face higher operating costs.

But despite the higher fuel costs, the company expects to see unit revenues grow by 8% to 10% in the first half of FY27.

And the experts appear to be bullish that the ASX 200 shares could be a turnaround story for FY27. Market Index data shows all brokers have a strong buy rating on Qantas shares. And the $11.31 average target price implies a potential 30% upside at the time of writing.

Paladin Energy Ltd (ASX: PDN)

Paladin Energy shares are rebounding on Thursday after a steep selloff over the past week.

The decline is likely due to a number of factors. These include geopolitical uncertainty and a drop in confidence for ASX uranium shares.

Renewed conflict in the Middle East, higher inflation data, and concerns about more interest-rate rises has seen some investors reduce their exposure to higher risk shares.

But despite the latest investor loss of confidence and share price declines, it looks like the experts are still very bullish about the outlook for Paladin Energy shares over the next 12 months.

Market Index data shows the majority of brokers still have a buy rating on the ASX 200 shares. At the $12.83 average target price implies an upside of around 35% at the time of writing.

CAR Group Ltd (ASX: CAR)

Shares in the ASX 200 technology company, which runs online global marketplaces for cars, motorcycles, boats and commercial vehicles, have tumbled around 20% over the past month.

The company has been hit by broad market volatility and investors taking their gains off the table after a rally following its FY26 results last month.

CAR Group’s FY26 results overall were positive. It reported FY26 revenue of $1.253 billion, up 6%, and NPAT of $314 million, up 14% on the prior year. Reported adjusted EBITDA was up 8% to $667 million. 

And looking ahead to FY27, CAR Group said it expects revenue growth of 11% to 14% and adjusted EBITDA growth of 10% to 13% on a constant currency basis. The company also plans for high single-digit revenue growth in Australia and double-digit growth in North America, Latin America and Asia.

The shares spiked around 10% on the day of the announcement, but have since tumbled back towards an annual low. 

But broker forecasts suggest the selloff was overdone and that the shares have the potential to rebound in the near future. Market Index data shows all brokers have a strong buy rating on the ASX 200 shares. And the $33.64 average target price implies an upside of around 40% at the time of writing.

The post 3 ASX 200 shares forecast to fly 30% to 40% higher appeared first on The Motley Fool Australia.

More reading

• These ASX 200 shares could return 50% to 85%
• Down 17% in a week: What has happened to Paladin Energy shares?
• Could I retire comfortably with $800,000 in superannuation?
• Why I’d invest $10,000 into Qantas shares today
• These are the 10 most shorted ASX shares

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended CAR Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Echo IQ Ltd (ASX: EIQ) jumped more than 10% after the company said it believed there was a “clear path” to obtaining regulatory approval in the US for its EchoSolv HF technology.

US roadblock not a dead end

Echo IQ shares fell almost 50% last week when the company revealed that the US Food & Drug Administration had issued a Not Substantially Equivalent determination for the company’s application for the approval of clinical use of EchoSolv HF.

But the company, having reviewed the situation, said on Thursday that work was underway with regulatory consultants and legal counsel about attaining regulatory approval.

The company said it “believes there is a clear path forward to obtaining FDA clearance for EchoSolv HF and it’s progressing this as a priority”.

The company added that the approval could be granted “over the coming quarters”.

Echo IQ said regarding the issue:

Following a review of the FDA’s feedback, the Company considers the matters cited to be limited to aspects of statistical analysis supporting the clinical validation. The Company’s assessment has not identified concerns relating to the underlying technology or core functionality of the EchoSolv HF device, and Echo IQ remains confident that clearance remains achievable under the 510(k) route. Echo IQ has identified multiple potential pathways to progress EchoSolv HF towards FDA clearance, including an administrative appeal of the NSE determination, seeking review through the FDA Ombudsman, or submitting a new 510(k) application.

The company said the timelines for an administrative appeal were not strictly defined, “and, in certain circumstances, may be shorter than 90 days”.

Echo IQ added:

If the Company were to file an administrative appeal, it may result in the NSE determination being overturned, the FDA reopening its review and potentially providing clearance of EchoSolv HF, or the FDA requesting that the Company resubmit a 510(k) for clearance, providing clarity on the matters Echo IQ must address to resolve the FDA’s previously identified concerns and obtain clearance.

EchoSolv HF is software that aims to improve the identification of patients at risk of heart failure.

The company recently said it remained well-funded, with more than $105 million in cash.

Shares bouncing back

Despite falling sharply on the recent news, Echo IQ shares have still appreciated 128% over a 12-month period.

The company’s shares were 10.7% higher at 57 cents on Thursday. They have traded as high as $1.87 and as low as 16.5 cents over the past year.

The company is valued at $381.6 million.   

The post Shares surge as ASX biotech charts road to redemption appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Echo IQ, James Hardie, Woolworths shares
• 6 ASX shares downgraded by brokers this week
• Morgans says these ASX shares could return 48% to 95%
• EchoIQ shares just crashed 48%. What happens now?
• Why has this ASX biotech fallen nearly 50% today?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares have climbed into the green in Thursday lunchtime trade. At the time of writing the ASX biotech shares are up around 1% and are changing hands for $176.50 each.

The shares have now jumped about 31% over the past month alone after rebounding strongly in August following the company’s FY26 results announcement.

CSL reported total revenue of US$15.8 billion and NPAT of US$2.6 billion. It also recorded a net loss after tax of US$2.6 billion for FY26, coming from pre-tax impairments and restructuring costs. The result came in way ahead of guidance and CSL management described FY26 as a ‘reset year’, with FY27 marking a return to growth.

A sectorwide rotation back into ASX healthcare shares has also helped boost CSL shares higher recently.

I think there is a lot of potential for the company to grow over the next few years. CSL is operating in a high-growth market, and its blood plasma division dominates the market for rare blood disorders and immunoglobulin products.

Analysts sentiment has also turned more positive. Market Index data shows the majority have a buy rating on CSL shares. But after the latest rally, the $159.86 average target price now implies a potential 8% downside ahead, at the time of writing.

The past month has seen CSL go from strength to strength, and the share price rebound is impressive.

But there is another ASX biotech stock I’d buy instead.

The ASX biotech stock I have my eye on right now

Telix Pharmaceuticals Ltd (ASX: TLX) is a little different from CSL. The two businesses are major Australian biotech companies but have a vastly different focus, scale, and market position.

CSL focuses on plasma therapies while Telix focuses on radiopharmaceuticals. In terms of size, CSL is a global industry giant with multi-billion-dollar revenues but Telix is a mid-size company in the midst of strong growth.

It’s Telix’s growth opportunities which I find most appealing. 

Its shares are in the spotlight this week after the company announced that its brain cancer imaging drug, Pixclara, has received approval from the US FDA. This makes it the first FET-PET imaging drug cleared for use in glioma and expands Telix’s precision medicine portfolio.

Telix says Pixclara is already the subject of a Phase 3 trial for diagnosis in additional brain conditions, with potential expansion to brain metastases. 

The company said it plans to target market leadership in both imaging and treatment for several high-need cancers.

Telix’s broader pipeline includes late-stage assets in prostate, kidney, and glioblastoma cancers, with a focus on bringing further precision medicine products to both existing and new markets worldwide.

The update came off the back of several other good-news announcements out of Telix so far this year, including an application for key regulatory approval in Europe, several announcements about its growth and development plans, news that FDA had accepted its NDA for TLX101-Px (Pixclara®), and the announcement of a major collaboration with US-based biotech company Regeneron Pharmaceuticals. 

Telix also posted an impressive first-half FY26 result last month. Highlights include a 22% increase in revenue to US$477 million, and a strong gross margin improvement to 55%. Adjusted EBITDA also surged 146% year-on-year to US$52 million.

What do brokers tip next for Telix Pharmaceuticals shares?

I think there is plenty more room for Telix shares to run higher this year. And it looks like brokers agree too.

TradingView data shows that 14 out of 16 analysts have a buy/strong buy rating on the shares. The average $25.48 target price implies a potential 45% upside, while the maximum $30.99 target price suggests the stock could climb 76%, at the time of writing.

The post Forget CSL shares, I’d buy this ASX biotech stock instead appeared first on The Motley Fool Australia.

More reading

• CSL acknowledges “disappointing” results but aims to do better
• CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded
• 4DMedical vs Telix Pharmaceuticals: ASX health tech share showdown
• Two broker upgrades put CSL shares back in focus
• Are Telix shares a buy after its big US FDA news?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Telix Pharmaceuticals. The Motley Fool Australia has recommended CSL and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.